Phase III Study Shows Novartis Drug Afinitor® More Than Doubles Time Without Tumor Growth In Advanced Pancreatic NET Patients
Submitted by MedicalReplies on Saturday, 3 July 2010No Comment
Novartis Pharmaceuticals Corporation (”Novartis”) announced that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3 (RAD001 In Advanced Neuroendocrine Tumors), was presented at the 12th World Congress on Gastrointestinal Cancer and is part of the largest clinical trial program in patients with advanced NET(1)…
Go here to read the rest:
Phase III Study Shows Novartis Drug Afinitor® More Than Doubles Time Without Tumor Growth In Advanced Pancreatic NET Patients
Leave your response!